Market Cap | 213.75M | P/E | - | EPS this Y | 53.30% | Ern Qtrly Grth | - |
Income | -72.5M | Forward P/E | -2.52 | EPS next Y | -3.30% | 50D Avg Chg | -27.00% |
Sales | 20.71M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -37.00% |
Dividend | N/A | Price/Book | 2.48 | EPS next 5Y | - | 52W High Chg | -66.00% |
Recommedations | 1.50 | Quick Ratio | 2.81 | Shares Outstanding | 41.55M | 52W Low Chg | 93.00% |
Insider Own | 28.68% | ROA | -49.37% | Shares Float | 22.51M | Beta | - |
Inst Own | 33.82% | ROE | -216.21% | Shares Shorted/Prior | 1.13M/1.12M | Price | 5.31 |
Gross Margin | -246.38% | Profit Margin | - | Avg. Volume | 348,912 | Target Price | 7.60 |
Oper. Margin | -126.89% | Earnings Date | Nov 7 | Volume | 130,613 | Change | -5.68% |
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
HC Wainwright & Co. | Buy | Jun 28, 24 |
HC Wainwright & Co. | Buy | Jun 26, 24 |
HC Wainwright & Co. | Buy | May 17, 24 |
HC Wainwright & Co. | Buy | May 10, 24 |
BTIG | Buy | Apr 11, 24 |
HC Wainwright & Co. | Buy | Apr 2, 24 |
HC Wainwright & Co. | Buy | Nov 29, 23 |
Capital One | Overweight | Oct 3, 23 |
HC Wainwright & Co. | Buy | Sep 6, 23 |